Therapeutic potential of endothelin receptor antagonism in kidney disease

Research output: Contribution to journalLiterature reviewpeer-review

Abstract

Our growing understanding of the role of the endothelin (ET) system in renal physiology and pathophysiology is from emerging studies of renal disease in animal models and humans. ET receptor antagonists reduce blood pressure and proteinuria in chronic kidney disease and cause regression of renal injury in animals. However, the therapeutic potential of ET receptor antagonism has not been fully explored and clinical studies have been largely limited to patients with diabetic nephropathy. There remains a need for more work in nondiabetic chronic kidney disease, end-stage renal disease (patients requiring maintenance dialysis and those with a functioning kidney transplant), ischemia reperfusion injury, and sickle cell disease. The current review summarizes the most recent advances in both preclinical and clinical studies of ET receptor antagonists in the field of kidney disease.

Original languageEnglish
Pages (from-to)R388-97
JournalAmerican Journal of Physiology - Regulatory, Integrative and Comparative Physiology
Volume310
Issue number5
DOIs
Publication statusPublished - 1 Mar 2016

Fingerprint Dive into the research topics of 'Therapeutic potential of endothelin receptor antagonism in kidney disease'. Together they form a unique fingerprint.

Cite this